Cargando…

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes

IMPORTANCE: Men with type 2 diabetes have an increased risk of cardiovascular disease (CVD). Meanwhile, gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer (PCa) are associated with increased risk of CVD. OBJECTIVE: To evaluate the association between GnRH agonist use, PCa diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, E., Garmo, Hans, Van Hemelrijck, Mieke, Zethelius, Björn, Stattin, Pär, Hagström, Emil, Adolfsson, Jan, Crawley, Danielle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361086/ https://www.ncbi.nlm.nih.gov/pubmed/35939302 http://dx.doi.org/10.1001/jamanetworkopen.2022.25600

Ejemplares similares

Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
por: Lin, E., et al.
Publicado: (2021)

Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
por: Lin, E., et al.
Publicado: (2022)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study
por: Lin, E., et al.
Publicado: (2020)

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
por: Crawley, Danielle, et al.
Publicado: (2018)

A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus
por: Crawley, Danielle, et al.
Publicado: (2018)

Causes of death in men with localized prostate cancer: a nationwide, population‐based study
por: Van Hemelrijck, Mieke, et al.
Publicado: (2015)

Mortality following Hip Fracture in Men with Prostate Cancer
por: Van Hemelrijck, Mieke, et al.
Publicado: (2013)

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0
por: Russell, Beth, et al.
Publicado: (2018)

Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
por: Häggström, Christel, et al.
Publicado: (2016)

Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study
por: Parker, Jonathan, et al.
Publicado: (2020)

Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
por: Van Hemelrijck, Mieke, et al.
Publicado: (2010)

Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases
por: George, Gincy, et al.
Publicado: (2020)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders
por: Eser, Ahmet, et al.
Publicado: (2018)

Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results
por: Beckmann, Kerri, et al.
Publicado: (2019)

Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory
por: Van Hemelrijck, Mieke, et al.
Publicado: (2016)

How to model temporal changes in comorbidity for cancer patients using prospective cohort data
por: Lindhagen, Lars, et al.
Publicado: (2015)

How to measure temporal changes in care pathways for chronic diseases using health care registry data
por: Ventimiglia, Eugenio, et al.
Publicado: (2019)

Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study
por: Beckmann, Kerri, et al.
Publicado: (2019)

Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden
por: George, Gincy, et al.
Publicado: (2023)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Transient Arterial Hypertension Induced by Gonadotropin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
por: Sifaki, Loukia, et al.
Publicado: (2019)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Outcome of intracytoplasmic sperm injection after preinstillation of a gonadotropin releasing hormone agonist in the uterine cavity just before embryo transfer
por: Çağlar Aytaç, Pınar, et al.
Publicado: (2017)

Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer
por: Kuo, Yong-fang, et al.
Publicado: (2008)

Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males
por: Van Hemelrijck, Mieke, et al.
Publicado: (2022)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial
por: Landgren, Valdemar, et al.
Publicado: (2020)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m7d8ac6a0bfrdab0pbvvdu5h5e